Heptapeptides used as anticarcinogenic agents


Ontology type: sgo:Patent     


Patent Info

DATE

2008-05-20T00:00

AUTHORS

TALLANT E ANN , GALLAGHER PATRICIA E , FERRARIO CARLOS M

ABSTRACT

The present invention describes the use of angiotensin-(1-7) peptide as an anti-cancer therapeutic. Thus, in one embodiment, the present invention comprises a composition to inhibit the growth of cancer cells in an individual comprising a pharmaceutically effective amount of an agonist for the angiotensin-(1-7) receptor to inhibit cancer cell growth or proliferation. Application of a pharmaceutically effective amount of angiotensin-(1-7) or angiotensin-(1-7) receptor agonist is associated with an increase in the expression of genes involved in tumor suppression, apoptosis, and/or cell cycle inhibition, and a decrease the expression of known oncogenes, protein kinases, and/or cell cycle progression genes. Cancers treated using the methods and compositions described herein include cancers having an angiotensin-(1-7) receptor, including, but not limited to, breast and lung cancer. More... »

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "name": "TALLANT E ANN", 
        "type": "Person"
      }, 
      {
        "name": "GALLAGHER PATRICIA E", 
        "type": "Person"
      }, 
      {
        "name": "FERRARIO CARLOS M", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/366704a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015821919", 
          "https://doi.org/10.1038/366704a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/375503a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034728495", 
          "https://doi.org/10.1038/375503a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/375247a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037354896", 
          "https://doi.org/10.1038/375247a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1385/cbb:34:1:17", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010348264", 
          "https://doi.org/10.1385/cbb:34:1:17"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-05-20T00:00", 
    "description": "

The present invention describes the use of angiotensin-(1-7) peptide as an anti-cancer therapeutic. Thus, in one embodiment, the present invention comprises a composition to inhibit the growth of cancer cells in an individual comprising a pharmaceutically effective amount of an agonist for the angiotensin-(1-7) receptor to inhibit cancer cell growth or proliferation. Application of a pharmaceutically effective amount of angiotensin-(1-7) or angiotensin-(1-7) receptor agonist is associated with an increase in the expression of genes involved in tumor suppression, apoptosis, and/or cell cycle inhibition, and a decrease the expression of known oncogenes, protein kinases, and/or cell cycle progression genes. Cancers treated using the methods and compositions described herein include cancers having an angiotensin-(1-7) receptor, including, but not limited to, breast and lung cancer.

", "endDate": "2023-04-20", "id": "sg:patent.US-7375073-B2", "name": "Heptapeptides used as anticarcinogenic agents", "recipient": [ { "id": "http://www.grid.ac/institutes/grid.412860.9", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/US-7375073-B2" ], "sdDataset": "patents", "sdDatePublished": "2022-08-04T17:25", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/patent/patent_39.jsonl", "type": "Patent" } ]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-7375073-B2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-7375073-B2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-7375073-B2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-7375073-B2'


 

This table displays all metadata directly associated to this object as RDF triples.

50 TRIPLES      15 PREDICATES      20 URIs      9 LITERALS      2 BLANK NODES

Subject Predicate Object
1 sg:patent.US-7375073-B2 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Nf6bbee12f66747879572c15e738f8400
4 schema:citation sg:pub.10.1038/366704a0
5 sg:pub.10.1038/375247a0
6 sg:pub.10.1038/375503a0
7 sg:pub.10.1385/cbb:34:1:17
8 schema:datePublished 2008-05-20T00:00
9 schema:description <p num="p-0001">The present invention describes the use of angiotensin-(1-7) peptide as an anti-cancer therapeutic. Thus, in one embodiment, the present invention comprises a composition to inhibit the growth of cancer cells in an individual comprising a pharmaceutically effective amount of an agonist for the angiotensin-(1-7) receptor to inhibit cancer cell growth or proliferation. Application of a pharmaceutically effective amount of angiotensin-(1-7) or angiotensin-(1-7) receptor agonist is associated with an increase in the expression of genes involved in tumor suppression, apoptosis, and/or cell cycle inhibition, and a decrease the expression of known oncogenes, protein kinases, and/or cell cycle progression genes. Cancers treated using the methods and compositions described herein include cancers having an angiotensin-(1-7) receptor, including, but not limited to, breast and lung cancer.</p>
10 schema:endDate 2023-04-20
11 schema:name Heptapeptides used as anticarcinogenic agents
12 schema:recipient grid-institutes:grid.412860.9
13 schema:sameAs https://app.dimensions.ai/details/patent/US-7375073-B2
14 schema:sdDatePublished 2022-08-04T17:25
15 schema:sdLicense https://scigraph.springernature.com/explorer/license/
16 schema:sdPublisher N29887f9e28924cfa9db056ed2aedc006
17 sgo:license sg:explorer/license/
18 sgo:sdDataset patents
19 rdf:type sgo:Patent
20 N19bd3c81095c4760beeba0751c1a8546 schema:name FERRARIO CARLOS M
21 rdf:type schema:Person
22 N25444367506b461aa4b59634e6abe068 rdf:first N19bd3c81095c4760beeba0751c1a8546
23 rdf:rest rdf:nil
24 N29887f9e28924cfa9db056ed2aedc006 schema:name Springer Nature - SN SciGraph project
25 rdf:type schema:Organization
26 N408643d6e5a741189f53eab48e724cb5 schema:name GALLAGHER PATRICIA E
27 rdf:type schema:Person
28 N581d9d6f3ef34ea1859b8d0bf2ad725d rdf:first N408643d6e5a741189f53eab48e724cb5
29 rdf:rest N25444367506b461aa4b59634e6abe068
30 Nc3a4efd62ca04f8e924273c4f1698256 schema:name TALLANT E ANN
31 rdf:type schema:Person
32 Nf6bbee12f66747879572c15e738f8400 rdf:first Nc3a4efd62ca04f8e924273c4f1698256
33 rdf:rest N581d9d6f3ef34ea1859b8d0bf2ad725d
34 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
35 rdf:type schema:DefinedTerm
36 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
37 rdf:type schema:DefinedTerm
38 sg:pub.10.1038/366704a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015821919
39 https://doi.org/10.1038/366704a0
40 rdf:type schema:CreativeWork
41 sg:pub.10.1038/375247a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037354896
42 https://doi.org/10.1038/375247a0
43 rdf:type schema:CreativeWork
44 sg:pub.10.1038/375503a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034728495
45 https://doi.org/10.1038/375503a0
46 rdf:type schema:CreativeWork
47 sg:pub.10.1385/cbb:34:1:17 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010348264
48 https://doi.org/10.1385/cbb:34:1:17
49 rdf:type schema:CreativeWork
50 grid-institutes:grid.412860.9 schema:Organization
 




Preview window. Press ESC to close (or click here)


...